Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16, FiscalAI reports. The company had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 44.42%.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• ARCT-810 completed Phase II enrollment and dosing in OTC deficiency, with U.S. and European data expected in Q3 2026 alongside FDA-requested supplementary data and an update on the regulatory path for adult and pediatric development.
• ARCT-032’s Phase II cystic fibrosis study remains on schedule, supported by expanded enrollment in Israel and Turkey; Arcturus expects to decide whether to advance to Phase III in Q4 2026, which would trigger substantial manufacturing and development support from Thermo Fisher.
• Arcturus regained global rights to KOSTAIVE and its broader self-amplifying mRNA vaccine portfolio after ending the CSL Seqirus collaboration. The settlement included a $12 million cash payment and release from approximately $16 million in liabilities, while returning strategic control that could enable commercialization and new partnerships.
• Revenue fell sharply to $3 million in Q2 2026 from $28.3 million a year earlier as the CSL collaboration wound down, while cash declined to $191.5 million from $230.8 million at year-end 2025.
• Management said the company has more than two and a half years of cash runway through year-end 2028, but it will need to balance rare-disease clinical spending with efforts to commercialize or partner the returned vaccine assets.

Arcturus Therapeutics Trading Up 21.9%

ARCT stock traded up $1.33 during midday trading on Friday, hitting $7.41. 1,461,125 shares of the company’s stock were exchanged, compared to its average volume of 442,082. The business has a 50-day simple moving average of $6.77 and a two-hundred day simple moving average of $7.38. The stock has a market capitalization of $210.59 million, a PE ratio of -2.24 and a beta of 2.39. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $24.17.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $24.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its holdings in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Arcturus Therapeutics by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock valued at $3,805,000 after buying an additional 2,098 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,586 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after buying an additional 2,857 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.